We advised GSK on the transaction

Davis Polk advised GSK in connection with an exclusive license agreement with Scynexis, Inc. pursuant to which GSK will receive an exclusive license to develop ibrexafungerp and commercialize BREXAFEMME in all countries except the greater China region and certain other countries already out-licensed by Scynexis to third parties. Scynexis retains rights to all other assets derived from enfumafungin. As part of this exclusive license agreement, GSK has been granted a right of first negotiation to these compounds. This agreement is conditional upon customary conditions including review by the appropriate regulatory agencies under the Hart-Scott-Rodino Act.

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.

Scynexis is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant.

The Davis Polk IP, tech and commercial transactions team included partner David R. Bauer and counsel Samantha Lefland. The corporate team included partner Daniel Brass and counsel Lisa Ogust Cammer. The tax team included partner William A. Curran. The antitrust and competition team included partner Jesse Solomon and counsel Mary K. Marks and Matthew Yeowart. The capital markets team included partner Yasin Keshvargar.  Members of the Davis Polk team are based in the New York, Washington DC and London offices.

Copy link to share post